First Human Trial Begins for Rare Brain Disorder SYNGAP1

A groundbreaking treatment for SYNGAP1, a rare genetic disease causing seizures and developmental delays, has entered human trials for the first time.

The therapy aims to restore a crucial brain protein that 1,800 identified patients worldwide currently lack.